Cancer Care Ontario | Cancer Care Ontario

438 Results

Guidelines and Advice

Systemic Treatment Emergency Preparedness Guidance Document

Status: Current

Updated

Aug 2025

Guidelines and Advice

Fluoropyrimidine Treatment in Patients with Dihydropyrimidine Dehydrogenase (DPD) Deficiency: Guidance for Clinicians

Status: Current
Version: 2

Updated

Sep 2025

Guidelines and Advice

Role of Adjuvant Treatment in Resected Pancreatic Ductal Adenocarcinoma

Status: Current
ID: GL 2-33
Version: 2

Jun 2025

Guidelines and Advice

Best-Practice Guidance for Radiation Treatment Plan Physics Review

Status: Current

Apr 2020

Guidelines and Advice

The Use of Molecular Tools for Identifying and Guiding Treatment of Cancers of Unknown Primary

Status: Current
ID: MOTAC-7

Jan 2025

Guidelines and Advice

An Endorsement of the 2025 Practical Guidelines for the Treatment of Gestational Trophoblastic Disease: Collaboration of the EOTTD, ESGO, GCIG, ISSTD

Status: Current
ID: GL END 4-19

Updated

Nov 2025

Guidelines and Advice

Recommendations for the Treatment of Patients with Clinical Stage III Non-Small Cell Lung Cancer: Endorsement of the 2019 National Institute for Health and Care Excellence Guidance and the 2018 Society for Immunotherapy of Cancer Guidance

Status: In-Review
ID: GL END 7-3
Version: 4

Apr 2020

Drug

durvalumab

Other Name(s): Imfinzi®

Quick Link(s):

Drug Monograph, Patient Info Sheet

May 2025

Guidelines and Advice

An Endorsement of the 2018 Guideline on Hypofractionated Radiation Therapy for Localized Prostate Cancer: An ASTRO, ASCO, and AUA Evidence-Based Guideline

Status: In-Review
ID: 3-22
Version: N/A

Apr 2020

Guidelines and Advice

Regional Therapies for Colorectal Cancer Liver Metastases

Status: Current
ID: GL 2-30a
Version: N/A

Mar 2020

Guidelines and Advice

An Endorsement of the 2023 International Stereotactic Radiosurgery Society’s (ISRS) Guideline: A Systematic Review Informing the Management of Symptomatic Brain Radiation Necrosis After Stereotactic Radiosurgery and ISRS Recommendations

Status: Current
ID: Guideline Endorsement C50-CIDAP-3

Mar 2025

Drug

atezolizumab

Other Name(s): Tecentriq™

Quick Link(s):

Drug Monograph, Patient Info Sheet

Jul 2025

Systemic Treatment Emergency Preparedness Guidance Document

Fluoropyrimidine Treatment in Patients with Dihydropyrimidine Dehydrogenase (DPD) Deficiency: Guidance for Clinicians

Role of Adjuvant Treatment in Resected Pancreatic Ductal Adenocarcinoma

Best-Practice Guidance for Radiation Treatment Plan Physics Review

The Use of Molecular Tools for Identifying and Guiding Treatment of Cancers of Unknown Primary

An Endorsement of the 2025 Practical Guidelines for the Treatment of Gestational Trophoblastic Disease: Collaboration of the EOTTD, ESGO, GCIG, ISSTD

Recommendations for the Treatment of Patients with Clinical Stage III Non-Small Cell Lung Cancer: Endorsement of the 2019 National Institute for Health and Care Excellence Guidance and the 2018 Society for Immunotherapy of Cancer Guidance

durvalumab

An Endorsement of the 2018 Guideline on Hypofractionated Radiation Therapy for Localized Prostate Cancer: An ASTRO, ASCO, and AUA Evidence-Based Guideline

Regional Therapies for Colorectal Cancer Liver Metastases

An Endorsement of the 2023 International Stereotactic Radiosurgery Society’s (ISRS) Guideline: A Systematic Review Informing the Management of Symptomatic Brain Radiation Necrosis After Stereotactic Radiosurgery and ISRS Recommendations

atezolizumab

Pages